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Abstract
Background—Children with Down syndrome (DS) have unique immune profiles and increased 
leukemia susceptibility.
Methods—Mothers of 158 children with DS diagnosed with acute leukemia at 0-19 years in 
1997-2002 and 173 children with DS but no leukemia were interviewed. Associations were 
evaluated via multivariable unconditional logistic regression.
Results—No associations were detected for asthma, eczema, allergies, or hypothyroidism. 
Diabetes mellitus associated with leukemia (odds ratio=9.23, 95% confidence interval: 
2.33-36.59), however most instances occurred concurrent with or after the leukemia diagnosis.
Conclusions and Impact—Children with DS who develop leukemia have increased diabetes 
risk, likely due to treatment and underlying susceptibility factors.
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Children with Down syndrome (DS) have 10- to 45-fold greater risk for developing acute 
leukemia compared with the general population.(1, 2) The extra copy of chromosome 21 is 
thought to be an important contributing factor, however, the mechanism behind this higher 
susceptibility is not well characterized.(3)
Children with DS are also known to have immune system dysregulation. Abnormalities in 
cell proportions and absolute counts have been reported, including reduced pools of naïve B 
cells, CD4+ and CD8+ T lymphocytes, and NK cells, and increased numbers of 
proinflammatory CD14dimCD16+ monocytes.(4) Differences in cytokine levels have also 
been observed.(5) For example, expression of interferon gamma, a cytokine central to the 
immune response to infectious pathogens and tumor cells, and its receptor IFNGR2, 
encoded on chromosome 21, are higher among children with DS.(6, 7) These differences 
correspond to an altered distribution of co-morbidities, where children with DS have 
increased rates of infections and autoimmunity (e.g., diabetes mellitus (DM), 
hypothyroidism), but develop atopy and asthma far less frequently than their euploid 
counterparts.(8, 9)
Several autoimmune diseases have been correlated with increased hematopoietic cancer risk.
(10, 11) In children, strong associations have been reported between DM and acute 
lymphoblastic leukemia (ALL); however, DM often presents after the leukemia diagnosis 
and may be self-limiting.(12, 13) Notably, the development of transient DM in ∼10% of 
ALL patients during treatment with L-asparaginase and glucocorticoids has been well 
documented.(14, 15) Presenting symptoms include hyperglycemia and, in rarer cases, 
diabetic ketoacidosis.(14) The DM is managed by monitoring glucose levels, administration 
of IV fluids, dietary modifications, increased exercise, and administration of insulin as 
needed.(15) Children with DS are one of the groups at higher risk of transient DM.(14) In a 
series of 421 childhood ALL patients, host factors associated with treatment-related 
hyperglycemia included DS (RR=7.17), age ≥10 years (RR=6.68), and obesity (RR=8.53).
(14) The DM often resolves after the discontinuation of the responsible therapeutic agent(s),
(14, 15) however, ALL survivors are at increased risk for chronic DM following treatment.
(16) To our knowledge, no prior studies have examined autoimmune diseases as risk factors 
for acute leukemia in children with DS.
There is ongoing debate regarding the nature of the association between atopic disease and 
childhood ALL, with most studies reporting inverse associations,(17) and other, record-base 
studies suggesting increased risks.(18, 19) Inverse associations with acute myeloid leukemia 
(AML) have also been observed for a smaller number of studies.(17) A recent case-control 
study in children with DS reported an increased odds of acute leukemia associated with 
asthma (OR=4.18, 95% CI: 1.47-11.87), and an inverse association with skin allergies 
(OR=0.42, 95% CI: 0.20-0.91).(20)
Here we tested the null hypothesis of no association between asthma, eczema, allergies, DM, 
or hypothyroidism in children with DS or their siblings, respectively, and acute leukemia.
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Methods for this Children's Oncology Group (COG) study have been described 
elsewhere(21) and are summarized below. Eligible cases had a prior DS diagnosis, an acute 
leukemia diagnosis between 0-19 years of age in 1/1/1997-10/31/2002 at a U.S. or Canadian 
COG institution, a residential telephone line, and a consenting biological mother that spoke 
English. Deceased cases were eligible.
After completing telephone interviews, case mothers were asked to provide contact 
information for the index child's primary care provider. Controls were randomly selected 
from rosters of children with DS generated by the cases' providers. Like cases, control 
children with a prior diagnosis of DS (but no cancer diagnosis), residential telephone line, 
and consenting biological mother that spoke English were eligible. Controls were frequency 
matched to cases in the age groupings: 0, 1-3, 4-6, 7-10, 11-14, and 15-18 years. DS and 
leukemia diagnoses were confirmed by central pathology review. To ensure similar 
exposure time periods for questions regarding childhood exposures in cases and controls, 
controls were randomly assigned a reference date in the 6 months prior to their birthday in 
the calendar year assigned in the frequency matching process; the pseudo-diagnosis date 
corresponded to the date exactly 6 months after the reference date. Similarly, the reference 
date assigned to cases was the date 6 months prior to the leukemia diagnosis.
Data on prior diagnosis of asthma, eczema, allergies, DM, thyroid conditions, and covariates 
were ascertained by maternal telephone interviews (ncases=158, ncontrols=173). Because these 
conditions are known to cluster within families and have substantial genetic contributions to 
the observed heritability,(22, 23) multiparous mothers were also asked if their other children 
had been diagnosed with these conditions (ncases=135, ncontrols=152).
Institutional Review Boards of the University of Minnesota and participating COG 
institutions approved the study.
Statistical Analysis
We estimated associations between the specified conditions and acute leukemia, overall and 
for ALL and AML separately, via multivariable unconditional logistic regression (SAS 9.2, 
SAS Institute Inc., Cary, NC, USA); odds ratios (ORs) and 95% confidence intervals (CIs) 
were generated for two time periods, any time and 6 months or more prior to leukemia 
diagnosis (cases) or pseudo-diagnosis date (controls). Reference age, the frequency 
matching variable, was included in all models. Possible confounders listed in Table 1 were 
selected a priori; those that changed the ln(ORs) by ≥10% were retained in final models.
Results
In total, 210 eligible cases were identified at 116 North American COG institutions and 158 
mothers completed interviews (97 ALL, 61 AML), for an overall response rate of 75%. Of 
the 215 mothers of eligible controls contacted, 173 participated (response rate=80.5%). 
Cases and controls were similar on several characteristics (Table 1), however, control 
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mothers tended to be slightly younger at the index child's birth, have higher educational 
attainment, and be non-Hispanic white compared with case mothers.
As shown in Tables 2 and 3, the adjusted logistic regression results provided little evidence 
for associations between immune-mediated conditions in index children or their siblings and 
development of acute leukemia, ALL, or AML. A notable exception was the strong positive 
association between DM in index children in any time period and acute leukemia overall 
(OR=9.23, 95% CI: 2.33-36.59); the estimate lacked precision, however, due to the limited 
number of affected subjects (15 cases, 3 controls). Because 14/15 cases (all of them with 
ALL) and 2/3 controls were diagnosed with DM <6 months preceding or after the leukemia 
diagnosis, the association was no longer observed in examining only DM diagnosed ≥6 
months prior to leukemia (OR=0.92; CI: 0.05-15.41).
A sensitivity analysis restricting cases to those with a control from the same primary care 
clinic (n=67) produced similar results (data not shown), thereby minimizing concerns 
regarding bias in control selection.
Discussion
In examining children with DS, a diagnosis of DM occurred 9 times more often in children 
who developed leukemia and occurred either concurrent with or after the leukemia 
diagnosis. These results are concordant with those from general population studies of 
pediatric ALL(14, 16, 24) and suggest that the development of or therapy for ALL induces 
the DM. That only 14/97 ALL patients acquired DM implicates additional genetic and/or 
environmental susceptibility factors. Notably, the Childhood Cancer Survivor Study 
reported increased risks for DM among ALL survivors receiving cranial irradiation and for 
AML survivors regardless of irradiation therapy,(16) while Hemminki et al argued for a 
common (yet to be identified) viral etiology.(13) Consistent with the results of Pui et al,(14) 
we observed a greater mean age at leukemia diagnosis in cases that developed diabetes 
(11.7+/-5.2 years) versus those that did not (3.9+/-3.2 years). Treatment and BMI data were 
not available for the current analysis.
Contrary to results from a similar study of children with DS(20) and with the inverse(17) 
and positive associations(18, 19) in studies examining allergic conditions and childhood 
ALL, we found no consistent associations for asthma, eczema, or other allergies.
The unique design of this study confers notable strengths. Given that COG institutions treat 
a large majority of pediatric leukemia cases,(25) the use of the COG registry to identify 
cases resulted in a nearly population-based study. Recruitment of healthy control children 
with DS from the cases' primary care clinics assured that controls served as reasonable 
proxies for cases had they not developed leukemia.
Rates of diabetes and hypothyroid disorders reported among our DS controls (2%, 19%, 
respectively) fall within the ranges reported by others (1-10%, 12-20%).(26, 27) The 
proportion of controls with asthma diagnoses (15%) was greater than prior reports (3%), 
suggesting the occurrence of recurrent wheeze due to non-atopic causes.(9) Given the 
severity of DM, thyroid conditions, and asthma, mothers would be expected to have high 
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recall of these conditions, while maternal report of eczema would be predicted to be lower.
(28, 29) Mothers of children with DS may have even higher recall than those in validation 
studies, since DS is associated with a complement of co-morbidities.(30) Notably, any 
misclassification of immune disorders would be expected to be non-differential, as case and 
control mothers would be similarly motivated in their recall.
An important limitation is the number of subjects that, when coupled with the rarity of the 
exposures, supplied limited statistical power to detect modest associations. In addition, the 
interview instrument did not collect exact date/age of DM diagnosis, or presentation, type or 
duration of DM, although treatment-induced, insulin-dependent, and noninsulin-dependent 
forms are all plausible.(14, 16, 31) Finally, given that children with DS have been shown to 
have different immune profiles from children without DS,(4-9) the findings from this study 
may not be generalizable to children without DS.
These null results indicate asthma, eczema, and hypothyroidism do not confer additional 
leukemia risk in children with DS, despite the unique cadre of immune-mediating conditions 
in this population. The DM association implicates the leukemia development or treatment in 
the etiology of DM and may reflect an underlying genetic susceptibility and/or 
environmental exposure.
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